Study of TACE Combined With Camrelizumab in the Treatment of HCC Patients
NCT04483284
·
clinicaltrials.gov ↗
PHASE2
Phase
ACTIVE_NOT_RECRUITING
Status
28
Enrollment
OTHER
Sponsor class
Conditions
Hepatocellular Carcinoma
Interventions
DRUG:
TACE combined with Camrelizumab
PROCEDURE:
TACE plus Camrelizumab
Sponsor
Shanghai Zhongshan Hospital